Moreover, CX-5461 exhibits single-agent efficacy in patient-derived HGSOC cells harboring a replication fork protection phenotype, a common mechanism of resistance to chemotherapy and PARP inhibitors [97], suggesting that CX-5461 through its p53-independent effects in activating the n-DDR can be harnessed to treat relapsed ovarian cancer. The gene discussed is PARP1; the disease is ovarian cancer.